Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-SATO PET/CT in pediatric neuroblastoma
2022-001811-16Phase 2Active
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Sep 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-satoreotide trizoxetan in neuroblastoma, sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Short-term safety and tolerability. Started Sep 2022; status: active.
02
Drugs
68Ga-satoreotide trizoxetan
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2022-001811-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001811-16.